Pruritis News and Research

RSS

Study suggests a single dose of JYNNEOS vaccine may lessen the severity of mpox illness

Researchers pursued evidence that the JYNNEOS vaccine offered some protection against the mpox disease, especially they confirmed the duration for which the one dose of this vaccine conferred protection.

3 Jan 2023

FLASH radiotherapy may hold promise as a potential treatment for tough-to-kill tumors

FLASH radiation treatment – which delivers therapeutic doses of radiation in a fraction of a second – may hold promise as a potential treatment for tough-to-kill tumors, a first-in-human study in a small number of people with bone cancer suggests.

24 Oct 2022

Could COVID-19 infections trigger a relapse of mycosis fungoides or other cutaneous T-cell lymphomas?

Recently, authors highlighted the potential role of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in triggering the relapse of mycosis fungoides, a type of cutaneous T-cell lymphoma.

17 Oct 2022

Study develops single-use microneedle patch tattoos with wide-ranging application potential

Researchers developed a rapid, sterile, and painless method of tattooing using single-use microneedle tattoo patches, which can be used for cosmetic and veterinary applications and storing medical information.

19 Sep 2022

CDC report shows people with monkeypox have higher than expected rates of HIV and STIs

Researchers investigated the prevalence of HIV, and other recent sexually transmitted infection diagnoses among persons with monkeypox.

12 Sep 2022

Clinical presentation of monkeypox infection in two Israeli males

Researchers described the symptomatology and clinical manifestations of monkeypox infections among two Israeli patients.

12 Jul 2022

Study investigates if COVID-19 restrictions were associated with differences in health and lifestyle of Labradors

A new study investigated whether COVID-19 restrictions were associated with differences in Dogslife Labrador Retrievers' lifestyle.

15 Feb 2022

Influenza and COVID vaccines can be co-administered in older adults without causing severe side effects

Researchers evaluate the safety and immunogenicity of an influenza vaccine and mRNA-based COVID-19 vaccine that were administered concomitantly.

3 Nov 2021

Symptom under-recognition may be common in breast cancer patients treated with radiotherapy

Among patients with breast cancer treated with radiotherapy, under-recognition of symptoms was common in reports of pain, pruritus, edema, and fatigue, with younger patients and Black patients having significantly increased odds of symptom under-recognition, according to data presented at the 2020 San Antonio Breast Cancer Symposium, held Dec. 8-11.

9 Dec 2020

Phase 2 IMAGO trial of SHP625 fails to meet primary endpoints in pediatric patients with ALGS

Shire plc today announced that the 13-week Phase 2 IMAGO trial of its investigational compound SHP625 (LUM001) did not meet the primary or secondary endpoints in the study of 20 pediatric patients with Alagille syndrome (ALGS), a rare, life-threatening genetic disorder that presents with chronic cholestasis (accumulation of bile acids in the liver) and severe pruritus (itching).

9 Apr 2015

Cipher acquires worldwide rights to three products from Astion

Cipher Pharmaceuticals Inc. today announced it has strengthened its product pipeline by acquiring the worldwide rights to three products from Astion Pharma, a Denmark-based specialty pharmaceutical company.

26 Feb 2015

Gilead reports topline results from sofosbuvir Phase 3 trial in Japan for treatment of HCV infection

Gilead Sciences, Inc. today announced topline results from a Phase 3 clinical trial (Study GS-US-334-0118) in Japan evaluating the once-daily nucleotide analog polymerase inhibitor sofosbuvir in combination with ribavirin (RBV) for the treatment of genotype 2 chronic hepatitis C virus (HCV) infection.

3 Apr 2014

Gilead Sciences gets marketing authorization from European Commission for Sovaldi 400 mg tablets

Gilead Sciences, Inc. today announced that the European Commission has granted marketing authorization for Sovaldi (sofosbuvir) 400 mg tablets, a once-daily oral nucleotide analogue polymerase inhibitor for the treatment of chronic hepatitis C infection in adults, in combination with other antiviral agents (ribavirin and pegylated interferon alpha (peg-IFN)).

18 Jan 2014

Immunologic checkpoint inhibitor shows promise in malignant mesothelioma

Tremelimumab, one of a new class of immunomodulatory monoclonal antibodies, has shown encouraging clinical activity and acceptable tolerability in patients with chemotherapy-resistant malignant mesothelioma, results of a single-arm phase II study show.

27 Sep 2013

Peripheral neuropathic pain patch treatments: an interview with Anne Hodgkins, Astellas Pharma

Peripheral neuropathic pain is caused by lesion or disease to the peripheral somatosensory nervous system. Nerve damage that can lead to peripheral neuropathic pain can happen as a result of a range of different diseases, medications or traumatic injuries.

8 May 2013

Gilead Sciences to present results from four Phase 3 clinical trials at International Liver Congress 2013

Gilead Sciences, Inc. today announced that detailed results from four Phase 3 clinical trials (NEUTRINO, FISSION, POSITRON and FUSION) evaluating sofosbuvir, the company's investigational once-daily nucleotide NS5B inhibitor for the treatment of chronic hepatitis C virus infection, will be presented this week in oral sessions at the 48th Annual Meeting of the European Association for the Study of the Liver in Amsterdam, The Netherlands.

23 Apr 2013

Study supports sphincter-saving surgery

Fissurectomy results in high levels of healing and low rates of anal incontinence, show the results of the largest ever prospective study of the technique.

26 Jul 2012

Multi-modal approach reduces pain and side effects of medication following joint replacement surgery

Reducing acute post-surgical pain and side effects of medications for patients undergoing knee and hip replacement surgery is the focus of a new multi-modal approach at Greenwich Hospital in Greenwich, Connecticut.

19 Jun 2012

ImmunoCellular receives U.S. patent allowance for ICT-107 to treat GBM

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, announced the allowance of U.S. patent claims related to ICT-107, the Company's dendritic cell based cancer vaccine candidate targeting multiple tumor antigens for the treatment of glioblastoma multiforme.

11 Oct 2011

ImmunoCellular announces updated long-term data from ICT-107 Phase I trial on GBM

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, today announced updated long-term data from a Phase I clinical trial of ICT-107, the Company's lead cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.

13 Sep 2011